Investigating how certain proteins interact in Alzheimer's disease
Official title: Eph and Lyn hyper-phosphorylation and CRMP interactions in AD"
Funded at Case Western Reserve University · NIH-10886829 · Data updated 2026-11-12
This study is looking at how certain proteins in the brain interact and change in ways that might contribute to Alzheimer's disease, with the hope of finding new ways to treat or diagnose the condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Case Western Reserve University NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | July 15, 2023 |
| Project end | June 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $201,250 |
| NIH project number | 5R21AG084065-02 |
| Project ID | NIH-10886829 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's may not benefit from this research.
What this research studies
This research focuses on understanding the interactions between Eph receptors and a protein called CRMP, which are believed to play a role in Alzheimer's disease. The study aims to explore how these proteins become hyper-phosphorylated and how this affects cell structure and function in the brain. By examining these interactions in a laboratory setting, researchers hope to identify potential biomarkers and therapeutic targets that could lead to new treatments for Alzheimer's. The research involves detailed analysis of protein behavior and cellular responses to better understand the underlying mechanisms of the disease.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating Alzheimer's disease.
How similar studies have gone: Previous research has shown promising results in understanding protein interactions in neurodegenerative diseases, suggesting potential for success in this area.
Where this research is happening
-
Case Western Reserve University
Cleveland, United States Active
Researchers
- Principal investigator: Buck, Matthias — Case Western Reserve University
- Study coordinator: Buck, Matthias
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.